Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

rd quarter; and finally, our plans to present the results of all seven cohorts of the INFORM-1 study at the AASLD meeting on November 3."

Results for the Three Months Ended June 30, 2009

InterMune reported total revenue in the second quarter of 2009 of $7.9 million, compared with total revenue of $8.1 million in the second quarter of 2008. Total revenue in the second quarter of 2009 primarily consisted of Actimmune(R) (interferon gamma-1b) revenue of $7.1 million, compared with $7.3 million in the same quarter of 2008, a decrease of approximately 2 percent, reflecting lower off-label physician prescriptions of Actimmune for the treatment of idiopathic pulmonary fibrosis (IPF), which InterMune does not promote.

Research and development (R&D) expenses in the second quarter of 2009 were $22.9 million compared with $25.4 million in the second quarter of 2008, a decrease of approximately 10 percent, reflecting completion of the CAPACITY clinical trials in early 2009, partially offset by expenses associated with the RECAP extension study and the preparation of the NDA and MAA for pirfenidone. General and administrative (G&A) expenses were $8.5 million in the second quarter of 2009, compared with $7.1 million in the same period a year earlier, an increase of approximately 20 percent, primarily attributed to costs related to preparation for the anticipated commercialization of pirfenidone.

InterMune recorded a loss on extinguishment of debt of $9.5 million, of which $8.9 million was non-cash, in the second quarter of 2009 in connection with the April 2009 exchange of approximately $32.3 million of its 0.25% Convertible Senior Notes due 2011 held by certain of its debt holders for shares of the company's common stock. A total of approximately 2.1 million shares of common stock were issued in connection with the transaction.

As of June 30, 2009, InterMune had cash, cash e
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... 19, 2014 The new , Healthcare ... , available today on PharmaBoardroom.com for free ... that rocked the Spanish economy in 2009, and the austerity ... has remained pragmatic in times of trouble. "Despite ... fifth biggest European market, and the general conditions to invest ...
(Date:9/18/2014)... September 18, 2014 A novel robotic ... MRI scanner is currently being tested as part of ... Hospital in Boston with the aim of determining if ... make prostate cancer biopsies faster, more accurate, less costly, ... also has the potential to deliver prostate cancer therapies ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Netherlands, August 4, 2011 SynCo Bio Partners ... today announced that its aseptic filling facility is again fully ... product batches for its clients after the expansion of its ... Class A zone is an important milestone in SynCo,s strategy ...
... An examination of the world,s largest river basins ... in the blooms of plankton associated with cholera outbreaks. ... increased temperature in coastal water, suggesting that predicting global ... complicated than first thought, according to a new study ...
... Corporation (Nasdaq: DNDN ) today reported results for ... the quarter ended June 30, 2011 was $49.6 million ... 30, 2010.  This included a $1.9 million reserve for ... or other pricing discounts offered pursuant to mandatory federal ...
Cached Biology Technology:SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Scientists pinpoint river flow associated with cholera outbreaks, not just global warming 2Scientists pinpoint river flow associated with cholera outbreaks, not just global warming 3Dendreon Reports Second Quarter 2011 Financial Results 2Dendreon Reports Second Quarter 2011 Financial Results 3Dendreon Reports Second Quarter 2011 Financial Results 4Dendreon Reports Second Quarter 2011 Financial Results 5Dendreon Reports Second Quarter 2011 Financial Results 6Dendreon Reports Second Quarter 2011 Financial Results 7Dendreon Reports Second Quarter 2011 Financial Results 8
(Date:9/18/2014)... Why is it that when people are too stressed ... Researchers from the Brain Mind Institute (BMI) at EPFL ... the relationship between chronic stress and the loss of ... an enzyme attacks a synaptic regulatory molecule in the ... Nature Communications . , Carmen Sandi,s team ...
(Date:9/18/2014)... Becoming invisible is probably the ultimate form of camouflage: ... you. And this strategy is not as uncommon as ... Maryland Baltimore County, USA, explains that the larval life ... is one part of the anatomy that most creatures ... compound eyes have to shield each individual eye unit ...
(Date:9/18/2014)... in the protective tentacles of host anemones, but new ... of kilometres across the open ocean. Although the process ... this is the first time that the high level ... , Dr Steve Simpson, Senior Lecturer in Marine Biology ... colleagues from the Australian Research Council Centre of Excellence ...
Breaking Biology News(10 mins):How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... Medical Center and CardioKinetix Inc., a medical device ... today announced promising results for the first-of-its-kind catheter-based ... Therapy (PVRT) technology for patients with ischemic heart ... were presented today (May 18, 2012, 9 a.m.) ...
... London have shown that zebrafish could be used to ... study, published online in the journal Behavioural Brain ... response to varying situations. Dr Caroline Brennan, from ... led the study, said: "Zebrafish are becoming one of ...
... 2012) By focusing on the identification of ... polymorphisms (SNPs) that predictwith a high degree of certainty--the ... (ASD) will also develop the condition. The findings ... ASD is among the most common form of ...
Cached Biology News:UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure 2UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure 3Zebrafish could hold the key to understanding psychiatric disorders 2Common genetic variants identify autism risk in high risk siblings of children with ASD 2Common genetic variants identify autism risk in high risk siblings of children with ASD 3Common genetic variants identify autism risk in high risk siblings of children with ASD 4
... enzyme-activity assay based on measurenment of enzyme ... antibody coated microtiter plate. The procedure includes ... or controls, 2nd enzyme reaction) separated ... intended for the determination of human enzymaticaly ...
... iEMS Incubator/Shaker HT is designed ... iEMS Incubator/Shaker HT is ideal ... hybridization and primer extension assays. ... as a one-cabinet model, allowing ...
... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... available as a one-cabinet model, ...
... is a modified cap analog in which ... is replaced with OCH3. Because of this ... transcription with the remaining hydroxyl group thus ... As a result, unlike transcripts synthesized with ...
Biology Products: